Salute e Benessere
Emphysema Market Analysis Reveals Promising Growth Opportunities and Trends During the Forecast Period (2025-2034) | DelveInsight
Discover the emphysema new treatment @
The increasing prevalence of COPD, including emphysema, is a primary driver. Factors such as smoking, air pollution, and genetic predispositions contribute to this rise. In 2024, DelveInsight estimated that the 7MM had around diagnosed cases of COPD, including approximately cases of emphysema, with prevalence projected to grow throughout the forecast period (2025–2034).
Innovations in pharmacological treatments, including bronchodilators, inhaled steroids, and biologics, have improved patient outcomes. Notably, drugs like and have shown efficacy in treating COPD and are expanding the therapeutic landscape.
Some of the emphysema drugs in clinical trials include (Sanofi), (Mereo BioPharma), (Beam Therapeutics), (Regeneron Pharmaceuticals/Sanofi), (GSK), (AstraZeneca), and others. The anticipated launch of these drugs will drive the emphysema market forward in the coming years.
Current emphysema management involves the use of bronchodilators (both short- and long-acting β2-agonists and anticholinergics), inhaled corticosteroids, phosphodiesterase-4 inhibitors, biologics such as (Verona Pharma) and (Regeneron Pharmaceuticals/Sanofi), combination therapies like (GSK), along with supportive interventions including pulmonary rehabilitation and oxygen therapy.
Despite these options, significant unmet needs remain in emphysema treatment. Challenges include limited disease-modifying therapies, inadequate control of exacerbations, variable patient responses, and a lack of long-acting therapies targeting the underlying inflammation and disease progression.
To address these gaps, new therapies such as (Regeneron Pharmaceuticals/Sanofi), (GSK), (AstraZeneca), and others are in development. These emerging treatments feature novel mechanisms of action and the potential for improved tolerability, potentially providing more durable benefits for patients who do not respond sufficiently to current therapies.
To know more about emphysema treatment options, visit @
Novel emphysema treatments, including (Sanofi), (Mereo BioPharma), (Beam Therapeutics), (Regeneron Pharmaceuticals/Sanofi), (GSK), (AstraZeneca), and others, are under development.
is an investigational therapy developed by Sanofi, representing a novel approach to the treatment of emphysema. Designed to address the underlying molecular mechanisms driving lung tissue damage and inflammation, SAR447537 aims to improve lung function and disease modification beyond current symptomatic treatments. The drug is currently active in Phase II for AATD emphysema.
is a Phase II investigational therapy developed by Mereo BioPharma, representing a novel approach to the treatment of emphysema. By inhibiting neutrophil elastase, a key enzyme involved in lung tissue destruction and inflammation, Alvelestat aims to preserve lung integrity, improve respiratory function, and slow disease progression beyond current symptomatic therapies.
is an investigational therapy developed by Beam Therapeutics, representing a novel gene-editing approach to the treatment of emphysema. Utilizing base-editing technology to precisely correct disease-causing mutations, BEAM-302 aims to restore alpha-1 antitrypsin function, reduce lung tissue damage, and offer a potentially curative solution beyond current symptomatic treatments.
is a fully human monoclonal antibody that targets and inhibits IL-33, a key initiator and amplifier of widespread inflammation in COPD. IL-33 is implicated in various forms of inflammation and is particularly elevated in the lungs of former smokers. Sanofi and Regeneron are co-developing Itepekimab through a global partnership.
is the first ultra-long-acting biologic in Phase III trials, exhibiting strong binding affinity and potency against interleukin-5 (IL-5), which enables dosing intervals of up to six months. IL-5 is a central cytokine in type 2 inflammation.
is a human monoclonal antibody with a dual mechanism that inhibits IL-33 via the ST2 and RAGE/EGFR pathways and has received from the US FDA. At the European Respiratory Society (ERS) 2024 meeting, AstraZeneca reported that the drug did not achieve the primary endpoint in a Phase II trial; nevertheless, as it had progressed to Phase III in populations showing stronger efficacy signals, the company remained confident in its potential.
The anticipated launch of these emerging therapies is poised to transform the emphysema market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the emphysema market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about therapy for emphysema @
Emphysema is a chronic, progressive lung condition and a type of chronic obstructive pulmonary disease (COPD). It is marked by permanent enlargement of the air spaces, destruction of alveolar walls, and reduced lung elasticity, resulting in restricted airflow and impaired gas exchange. The disease is mainly caused by prolonged exposure to harmful inhalants, with cigarette smoke being the most common culprit. However, environmental pollutants, biomass fuels, e-cigarettes, repeated lung infections, and secondhand smoke can also contribute. A rare genetic disorder, alpha-1 antitrypsin deficiency, can lead to early-onset emphysema. COPD, which encompasses emphysema and chronic bronchitis, remains a major cause of mortality globally.
The emphysema epidemiology section provides insights into the historical and current emphysema patient pool and forecasted trends for the leading markets. In 2024, the US accounted for an estimated diagnosed cases of emphysema within the 7MM.
The emphysema market report proffers epidemiological analysis for the study period 2020–2034 in the leading markets, segmented into:
Download the report to understand which factors are driving emphysema therapeutics market trends @
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key emphysema companies, including among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key COPD companies including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key COPD companies, including among others.
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key COPD treatment devices companies, including , among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/emphysema-market-analysis-reveals-promising-growth-opportunities-and-trends-during-the-forecast-period-20252034--delveinsight-302589975.html